Danaher Co. (NYSE:DHR) Shares Bought by Manitou Investment Management Ltd.

Manitou Investment Management Ltd. lifted its position in shares of Danaher Co. (NYSE:DHR) by 496.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,204 shares of the conglomerate’s stock after buying an additional 76,755 shares during the quarter. Danaher comprises about 4.9% of Manitou Investment Management Ltd.’s holdings, making the stock its 10th largest position. Manitou Investment Management Ltd.’s holdings in Danaher were worth $25,635,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after acquiring an additional 4,163,657 shares in the last quarter. Swedbank AB bought a new position in shares of Danaher in the first quarter valued at $676,545,000. TD Asset Management Inc lifted its stake in shares of Danaher by 99.0% in the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after buying an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its stake in shares of Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after buying an additional 428,897 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 1.4 %

Shares of DHR stock opened at $245.66 on Friday. The company’s fifty day simple moving average is $267.38 and its two-hundred day simple moving average is $260.32. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $188.75 and a 1 year high of $281.70. The stock has a market capitalization of $177.44 billion, a price-to-earnings ratio of 46.88, a PEG ratio of 4.45 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.02 EPS. As a group, analysts anticipate that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s payout ratio is currently 20.61%.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DHR shares. Evercore ISI raised their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stephens reaffirmed an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Barclays dropped their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Robert W. Baird dropped their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, UBS Group dropped their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.